Table 1.

Baseline characteristics for patients enrolled in COAST-X

	PBO (N = 105)	IXE Q4W (N = 96)	IXE Q2W (N = 102)
Age, years	39.9 (12.4)	40.9 (14.5)	40.0 (12.0)
Male, n (%)	44 (41.9)	50 (52.1)	49 (48.0)
Weight, kg	75.8 (18.4)a	79.5 (16.5)	77.3 (16.6)
Duration of nr-axSpA symptoms, years	10.1 (8.3)	11.3 (10.7)	10.6 (10.1)
Time since nr-axSpA diagnosis, years	3.1 (4.5)	4.2 (5.5)	3.4 (4.6)
CRP, mg/l	14.3 (24.4)	12.4 (18.0)	12.1 (17.8)
Screening MRI/CRP status, n (%)
Positive MRI and elevated CRP	38 (36.2)	30 (31.3)	39 (38.2)
Positive MRI and non-elevated CRP	40 (38.1)	36 (37.5)	34 (33.3)
Negative MRI and elevated CRP	26 (24.8)	30 (31.3)	28 (27.5)
Therapy, n (%)
Current cDMARD use, including MTX	36 (34.3)	40 (41.7)	42 (41.2)
Current MTX use	17 (16.2)	17 (17.7)	15 (14.7)
ASDAS	3.8 (0.9)	3.8 (0.8)	3.9 (0.8)
Patient global disease activity	7.4 (1.7)	7.1 (1.7)	7.6 (1.5)
Spinal pain NRS	7.4 (1.6)	7.3 (1.7)	7.4 (1.6)
Function, BASFI	6.7 (2.0)	6.4 (2.1)	6.5 (1.8)
Stiffness, BASDAI questions 5 and 6	7.0 (1.9)	6.8 (2.0)	7.1 (1.5)
Fatigue NRS	7.1 (1.8)	7.2 (1.6)	7.2 (1.8)
BASDAI fatigue	7.4 (1.6)	7.4 (1.6)	7.5 (1.6)
Spinal pain at night NRS	7.3 (1.7)	7.0 (1.9)	7.5 (1.8)

^aNx = 104

Data are mean (SD) unless otherwise stated. Percentage was calculated by n/N*100%

ASDAS Ankylosing Spondylitis Disease Activity Score, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, cDMARD conventional disease-modifying anti-rheumatic drug, CRP C-reactive protein, MRI magnetic resonance imaging, IXE Q2W 80-mg ixekizumab every 2 weeks, IXE Q4W 80-mg ixekizumab every 4 weeks, MTX methotrexate, N number of patients in the analysis category, n number of patients in subgroup, NRS numeric rating scale, nr-axSpA non-radiographic axial spondyloarthritis, PBO placebo, SD standard deviation